object
investig
risk
factor
empyema
acut
viral
infect
clarifi
hypothes
associ
empyema
virus
andor
use
nonsteroid
antiinflammatori
drug
nsaid
casecontrol
studi
conduct
center
case
control
enrol
sourc
popul
children
year
age
acut
viral
infect
result
among
empyema
case
children
empyema
acut
viral
infect
within
preced
day
includ
control
children
acut
viral
infect
match
case
consid
intak
drug
within
hour
acut
viral
infect
onset
least
consecut
day
antibiot
use
least
day
nsaid
exposur
multivari
analysi
retain
increas
risk
empyema
associ
nsaid
exposur
aor
ci
p
decreas
risk
associ
antibiot
use
aor
ci
p
risk
empyema
associ
nsaid
exposur
greater
children
prescrib
antibiot
antibiot
intak
diminish
risk
children
given
nsaid
conclus
nsaid
use
acut
viral
infect
associ
increas
risk
empyema
children
antibiot
associ
decreas
risk
presenc
antibioticnsaid
interact
risk
suggest
find
suggest
nsaid
recommend
firstlin
antipyret
treatment
acut
viral
infect
children
j
pediatr
lthough
rel
infrequ
empyema
seriou
bacteri
infect
pleural
space
remain
caus
substanti
morbid
inhospit
casefat
ratio
children
late
diagnosi
onset
appropri
therapi
contribut
increas
morbid
addit
inhospit
manag
patient
empyema
associ
substanti
econom
cost
incid
rate
empyema
children
increas
worldwid
franc
without
clear
explan
trend
modifi
pneumococc
conjug
vaccin
program
hospit
uncompl
pneumonia
clearli
declin
thereaft
previou
retrospect
studi
suggest
use
nonsteroid
antiinflammatori
drug
nsaid
communityacquir
pneumonia
may
associ
increas
risk
empyema
protopath
bia
could
exclud
casecontrol
studi
undertaken
investig
children
risk
factor
empyema
acut
viral
infect
determin
whether
virus
use
nsaid
associ
studi
approv
institut
review
board
univers
hospit
neckerenf
malad
particip
parent
case
control
children
older
year
age
given
oral
written
inform
provid
written
consent
match
casecontrol
studi
includ
case
control
sourc
popul
children
acut
viral
infect
conduct
french
pediatr
respiratori
clinic
depart
septemb
june
acut
viral
infect
diagnos
clinic
symptom
provid
follow
acut
viral
infect
follow
herp
viru
infect
varicella
gastroenter
defin
acut
diarrhea
least
loos
stool
per
day
nasopharyng
defin
runni
nose
nasal
congest
cough
bronchiol
defin
cough
short
breath
wheez
auscult
flulik
syndrom
defin
cough
fever
myalgia
bronchiti
defin
cough
bronchial
congest
viral
pharyng
document
neg
test
rapid
diagnosi
group
streptococc
infect
acut
viral
infect
divid
group
upper
respiratori
tract
viral
infect
lower
respiratori
tract
viral
infect
lrtvi
bronchiol
bronchiti
flu
other
acut
viral
infect
sever
requir
hospit
consecut
patient
month
year
age
hospit
empyema
particip
center
elig
empyema
defin
presenc
pleural
effus
chest
radiograph
least
follow
result
test
pleural
fluid
ph
lactat
dehydrogenas
iul
glucos
mmoll
protein
mgdl
white
blood
cell
count
cellsml
andor
posit
bacteri
cultur
gram
stain
case
empyema
follow
doctordiagnos
acut
viral
infect
base
clinic
symptom
identifi
within
maximum
day
preced
date
first
pleural
punctur
control
children
month
year
age
acut
viral
infect
sourc
popul
case
children
defin
children
evalu
privat
practition
acut
viral
infect
control
recruit
follow
upon
case
identif
doctor
refer
child
hospit
contact
identifi
among
hisher
patient
children
match
age
year
consult
viral
symptom
preced
day
similar
time
window
match
case
figur
avail
wwwjpedscom
exclus
criteria
case
control
chronic
respiratori
diseas
acquir
andor
congenit
immunolog
disord
malign
collagen
vascular
diseas
sickl
cell
diseas
congenit
heart
defect
neuromuscular
diseas
hemophilia
andor
heart
failur
treatment
corticosteroid
immunosuppress
agent
month
preced
identif
known
intoler
nsaid
acetaminophen
exclus
criteria
case
absenc
least
hour
apyrexia
recov
lrtvi
symptom
diagnosi
empyema
time
onset
acut
viral
infect
diagnosi
empyema
hour
decreas
possibl
symptom
onset
possibl
onset
bacteri
infect
hospit
case
question
parent
train
doctor
nurs
complet
detail
standard
form
record
symptom
treatment
concern
period
onset
acut
viral
infect
first
day
clinic
symptom
empyema
diagnosi
pleural
punctur
correspond
time
exposur
control
parent
contact
consult
treat
physician
data
record
retrospect
exactli
done
case
detail
standard
form
record
clinic
item
concern
exposur
windowtim
acut
viral
infect
onset
match
case
primari
provid
went
control
home
obtain
nasal
swab
specimen
record
data
figur
symptom
treatment
antibiot
glucocorticoid
nsaid
acetaminophen
accord
doctor
prescript
selfadminist
medic
record
daili
follow
inform
also
record
enrol
children
demograph
immun
statu
type
acut
viral
infect
state
doctor
addit
nasal
swab
obtain
respiratori
viru
screen
case
initi
clinic
find
result
biochemistri
microbiolog
test
radiograph
find
manag
length
stay
record
two
doctor
review
medic
record
identifi
patient
independ
valid
case
identif
laboratori
hospit
case
admit
bacteri
strain
pleural
fluid
sent
ident
confirm
univers
hospit
neckerenf
malad
microbiolog
laboratori
feasibl
sampl
pleural
fluid
sent
pneumococc
antigen
test
polymeras
chain
reaction
pcr
test
atyp
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
cultur
neg
pneumococc
univers
bacteri
pcr
perform
dna
extract
ml
pleural
fluid
sampl
previous
store
c
autom
magna
pure
lc
system
roch
diagnost
meylan
franc
elut
ml
elut
buffer
use
dna
iii
magna
pure
dna
isol
kit
roch
diagnost
inhous
c
pneumonia
gene
pneumonia
cytadhesin
gene
pcr
perform
describ
previous
pneumonia
pneumolysin
gene
realtim
pcr
perform
accord
corless
et
al
neg
pneumococc
pcr
sampl
realtim
amplif
univers
bacteri
rdna
perform
amplifi
product
sequenc
previous
report
pneumococc
antigen
detect
immunochromatograph
test
binaxnow
streptococcu
pneumonia
binax
inc
portland
main
accord
le
monnier
et
al
pneumococc
strain
serotyp
french
nation
refer
center
pneumococci
nrcp
via
use
latex
particl
coat
complet
panel
antisera
factor
serum
provid
staten
serum
institut
copenhagen
denmark
abl
identifi
known
serotyp
pneumococc
strain
known
serotyp
staten
serum
institut
french
nrcp
use
intern
control
avail
dna
individu
pleural
fluid
sampl
posit
pneumolysin
pcr
also
sent
nrcp
serotyp
convent
multiplex
pcr
pcr
pcrproduct
detect
agaros
gel
perform
describ
center
diseas
control
prevent
http
wwwcdcgovncidodbiotechstreppcrhtm
nasal
swab
deposit
ml
transport
medium
contain
g
tryptos
phosphat
broth
becton
dickinson
le
pont
de
claix
franc
g
gelatin
becton
dickinson
unit
penicillin
mg
streptomycin
mg
amphotericin
b
antibiot
antimycot
solut
sigma
saintquentinfallavi
franc
viral
rna
dna
isol
autom
magna
pure
lc
system
roch
diagnost
ml
nasal
sampl
elut
ml
elut
buffer
via
total
nucleic
acid
isol
kit
roch
diagnost
inhous
realtim
pcr
use
detect
adenovirus
previous
describ
inhous
realtim
revers
transcript
pcr
use
detect
metapneumoviru
influenza
viru
b
parainfluenza
virus
respiratori
syncyti
virus
b
rhinoviru
report
elsewher
analysi
phase
consid
drug
exposur
onset
acut
viral
infect
symptom
drug
use
consid
exposur
began
within
hour
onset
acut
viral
infect
apyrexia
lrtvi
control
period
time
risk
drug
exposur
defin
time
onset
acut
viral
infect
empyema
diagnosi
pair
case
drug
exposuredur
consid
least
consecut
day
antibiot
consecut
day
nsaid
acetaminophen
condit
logist
regress
use
compar
case
match
control
gener
characterist
variabl
achiev
p
includ
multivari
analysi
estim
match
or
propos
exposur
definit
use
pvalu
threshold
final
model
determin
via
manual
backwardselect
procedur
appropri
interact
variabl
test
specif
use
subgroup
model
thoroughli
investig
interact
final
signific
variabl
condit
logist
model
converg
unpair
classic
logist
regress
use
case
compar
condit
logist
model
greater
signific
might
observ
p
multivari
model
defin
signific
comput
made
stata
softwar
statacorp
colleg
station
texa
potenti
case
potenti
control
match
pair
elig
case
control
identifi
figur
avail
wwwjpedscom
group
boy
mean
durat
exposur
defin
delay
onset
acut
viral
infect
diagnosi
empyema
case
day
signific
differ
observ
case
control
age
sibl
parent
occup
acut
viral
infect
site
vaccin
fever
acut
viral
infect
onset
tabl
acut
viral
infect
mostli
upper
respiratori
tract
viral
infect
onehalf
subject
group
receiv
least
dose
children
respiratori
viral
identif
differ
found
type
virus
identifi
case
control
tabl
ii
avail
wwwjpedscom
among
case
identifi
bacteria
pneumonia
account
figur
avail
wwwjpedscom
among
pneumonia
identifi
serotyp
n
serotyp
frequent
vast
major
belong
vaccin
serotyp
figur
avail
wwwjpedscom
consid
drug
exposuredur
day
antibiot
consecut
day
nsaid
interv
onset
acut
viral
infect
start
treatment
hour
drug
nsaid
systemat
use
often
antibiot
systemat
less
often
case
control
acetaminophen
also
prescrib
frequent
case
control
particularli
taken
least
consecut
day
tabl
iii
consid
drugus
onset
within
hour
onset
acut
viral
infect
least
consecut
day
antibiot
use
least
day
nsaid
antipyret
exposur
multivari
analysi
retain
increas
risk
empyema
associ
nsaid
exposur
aor
p
decreas
risk
empyema
associ
antibiot
aor
p
tabl
iv
associ
acetaminophen
interact
antibiot
use
nsaid
exposur
statist
signific
link
empyema
p
subgroup
analys
carri
examin
potenti
interact
antibiot
nsaid
use
empyema
show
risk
empyema
associ
nsaid
greater
antibiot
use
less
consecut
day
uncondit
aor
p
empyema
risk
associ
antibiot
lower
subgroup
children
expos
nsaid
uncondit
aor
p
compar
children
unexpos
nsaid
tabl
v
avail
wwwjpedscom
casecontrol
studi
provid
strong
support
increas
risk
empyema
children
acut
viral
infect
expos
nsaid
nsaid
previous
suspect
risk
factor
sever
bacteri
infect
biolog
mechan
nsaid
influenc
pathogenesi
bacteri
infect
remain
controversi
base
abil
nsaid
modifi
host
inflammatori
pathway
innat
immun
respons
direct
role
nsaid
develop
sever
group
streptococc
infect
propos
steven
hypothesi
base
abil
nsaid
induc
increas
product
cytokin
tumor
necrosi
factor
interleukin
interleukin
observ
nsaid
may
inhibitori
action
leukocyt
adhes
phagocytosi
bactericid
activ
vitro
final
observ
low
concentr
ibuprofen
obtain
antipyret
use
may
proinflammatori
action
promot
recruit
influx
neutrophil
use
nsaid
also
reflect
delay
effect
treatment
nsaid
might
mask
onset
bacteri
diseas
decreas
inflammatori
respons
infect
associ
bacteri
infect
nsaid
report
necrot
fasciiti
primari
varicella
invas
group
streptococc
infect
occurr
new
symptom
complic
slightli
frequent
children
receiv
ibuprofen
advis
take
acetaminophen
respiratori
tract
infect
empyema
thought
associ
outpati
use
nsaid
children
adult
howev
nsaid
could
causal
implic
analysi
hamper
protopath
bia
ie
possibl
frequent
use
nsaid
patient
develop
empyema
febril
sever
earli
infect
uncompl
acut
bacteri
pneumonia
imposs
clearli
state
whether
nsaid
start
empyema
onset
strength
casecontrol
studi
specif
design
minim
bia
much
possibl
first
pair
case
control
sourc
popul
children
initi
acut
viral
infect
could
lead
antipyret
exposur
diagnos
physician
control
recruit
doctor
physicianrel
geograph
variat
exposur
control
second
lrtvi
avoid
protopath
bia
much
possibl
children
without
least
hour
apyrexia
recoveri
lrtvi
symptom
diagnosi
empyema
exclud
third
time
onset
acut
viral
infect
diagnosi
empyema
less
hour
children
exclud
avoid
drug
exposur
pyrexia
andor
pain
link
empyema
onset
fourth
analysi
phase
consid
drug
exposur
first
drug
intak
occur
within
hour
onset
acut
viral
infect
symptom
increas
risk
empyema
associ
nsaid
intak
acut
viral
infect
primari
observ
fact
associ
signific
first
day
nsaid
use
strengthen
result
studi
limit
noteworthi
rel
small
number
case
control
limit
statist
power
identifi
associ
rel
difficult
find
match
control
despit
effort
primari
provid
addit
daili
dosag
medicin
taken
precis
enough
permit
analysi
dose
effect
diminish
risk
empyema
associ
antibiot
treatment
acut
viral
infect
second
import
observ
reduc
risk
pneumonia
antibiot
treatment
lrtvi
report
previous
antibiot
slightli
diminish
risk
suppur
complic
acut
sore
throat
adult
mastoid
otiti
children
studi
antibiot
exposur
reach
signific
therapi
given
least
day
physician
indic
prescrib
antibiot
known
acetaminophen
impact
empyema
lack
find
signific
interact
antibiot
plu
nsaid
empyema
like
relat
lack
power
small
number
subject
still
risk
empyema
associ
nsaid
exposur
greater
children
prescrib
antibiot
antibiot
intak
reduc
risk
children
given
nsaid
nsaid
recommend
antipyret
use
wide
acut
viral
infect
children
also
sold
overthecount
mani
year
nsaid
constitut
one
wide
use
class
drug
probabl
sever
million
prescript
sever
billion
overthecount
tablet
sold
children
antipyret
develop
countri
regardless
efficaci
drug
control
fever
result
suggest
use
associ
complic
bacteri
infect
associ
acut
viral
infect
reconsid
acut
viral
infect
like
enhanc
risk
bacteri
infect
may
vari
viru
syndrom
reduc
bia
case
control
match
initi
viral
syndrom
moreov
viru
detect
rate
virus
identifi
similar
case
control
suggest
viral
speci
caus
acut
viral
infect
influenc
complic
empyema
increas
incid
empyema
report
mani
countri
author
suggest
phenomenon
caus
dissemin
particular
pathogen
pneumonia
studi
pathogen
associ
empyema
pneumonia
streptococcu
pyogen
staphylococcu
aureu
find
strongli
argu
oligoclon
monoclon
phenomenon
pneumonia
serotyp
divers
mostli
serotyp
patient
similar
observ
empyema
invas
pneumonia
infect
franc
domin
serotyp
observ
result
strongli
support
idea
nsaid
increas
risk
empyema
children
previou
acut
viral
infect
suggest
nsaid
interact
antibiot
find
suggest
nsaid
recommend
firstlin
antipyret
treatment
acut
viral
infect
children
n
thank
studi
scientif
advisori
board
provid
use
advic
lucien
abenhaim
previous
employ
pari
descart
